{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:08:13Z","timestamp":1786993693540,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010527","name":"Universit\u00c3\u00a9 Libre de Bruxelles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010527","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.lungcan.2018.10.018","type":"journal-article","created":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T17:42:10Z","timestamp":1539884530000},"page":"25-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["Systemic treatments for thymoma and thymic carcinoma: A systematic review"],"prefix":"10.1016","volume":"126","author":[{"given":"Thierry","family":"Berghmans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Durieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Holbrechts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Jungels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Lafitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Pascale","family":"Meert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebahat","family":"Ocak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Roelandts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2018.10.018_bib0005","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ejca.2012.02.047","article-title":"Rare thoracic cancers, including peritoneum mesothelioma","volume":"48","author":"Siesling","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2018.10.018_bib0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jtho.2015.09.007","article-title":"Are anthracycline-based regimens truly indicated to be the standard chemotherapy regimen for thymic carcinoma?","volume":"11","author":"Hirai","year":"2016","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00432-014-1800-6","article-title":"Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy","volume":"141","author":"Okuma","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0020","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ctrv.2013.11.003","article-title":"Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review","volume":"40","author":"Berardi","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0025","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/JTO.0b013e3181a4b8e0","article-title":"The management of thymoma: a systematic review and practice guideline","volume":"4","author":"Falkson","year":"2009","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0030","series-title":"Evidence-based Medicine: How to Practice and Teach EBM","author":"Sackett","year":"2000"},{"key":"10.1016\/j.lungcan.2018.10.018_bib0035","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0021-9681(61)90060-1","article-title":"The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent","volume":"13","author":"Gehan","year":"1961","journal-title":"J. Chronic Dis."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0040","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/cncr.22404","article-title":"Topoisomerase 2alpha plays a pivotal role in the tumor biology of stage IV thymic neoplasia","volume":"109","author":"Liu","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2018.10.018_bib0045","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.ejcts.2009.11.001","article-title":"Predictors of survival in patients with locally advanced thymoma and thymic carcinoma (Masaoka stages III and IVa)","volume":"37","author":"Cardillo","year":"2010","journal-title":"Eur. J. Cardio-thoracic Surg."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0050","first-page":"208","article-title":"Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results","volume":"25","author":"Oshita","year":"1995","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0055","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-14-0968","article-title":"A phase I\/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study","volume":"20","author":"Thomas","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0060","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/JTO.0000000000000362","article-title":"Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: north Japan Lung Cancer group study 0803","volume":"9","author":"Inoue","year":"2014","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0065","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial","volume":"91","author":"Loehrer","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2018.10.018_bib0070","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/JTO.0b013e3181db3dee","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience","volume":"5","author":"Grassin","year":"2010","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0075","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0080","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/JTO.0b013e318292c41e","article-title":"A prospective phase II trial of induction chemotherapy with docetaxel\/cisplatin for Masaoka stage III\/IV thymic epithelial tumors","volume":"8","author":"Park","year":"2013","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0085","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1097\/JTO.0000000000000692","article-title":"A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors","volume":"10","author":"Kim","year":"2015","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0090","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2217\/fon.14.144","article-title":"Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial","volume":"10","author":"Palmieri","year":"2014","journal-title":"Future Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0095","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2016.06.020","article-title":"Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): a single-institution experience","volume":"99","author":"Bluthgen","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2018.10.018_bib0100","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0105","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.2147\/OTT.S105949","article-title":"Efficacy of pemetrexed-based regimen in relapsed advanced thymic epithelial tumors and its association with thymidylate synthetase level","volume":"9","author":"Qian","year":"2016","journal-title":"Onco. Ther."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0110","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2014.11.006","article-title":"Pemetrexed in patients with thymic malignancies previously treated with chemotherapy","volume":"87","author":"Liang","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2018.10.018_bib0115","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","article-title":"Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial","volume":"15","author":"Rajan","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0120","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.[Erratum appears in Lancet Oncol. 2015 Mar;16(3):e105; PMID: 25752557]","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0125","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2016.04.024","article-title":"Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network","volume":"97","author":"Remon","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2018.10.018_bib0130","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0135","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/cncr.10374","article-title":"Somatostatin analogs and prednisone in advanced refractory thymic tumors","volume":"94","author":"Palmieri","year":"2002","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.lungcan.2018.10.018_bib0140","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. [Erratum appears in J Clin Oncol. 2004 Jun 1;22(11):2261]","author":"Loehrer","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0145","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00000421-199308000-00014","article-title":"EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma","volume":"16","author":"Bonomi","year":"1993","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0150","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.1999.17.9.2737","article-title":"Treatment of invasive thymoma with single-agent ifosfamide","volume":"17","author":"Highley","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0155","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12885-016-2159-7","article-title":"Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma.[Erratum appears in BMC Cancer. 2016;16(1):272; PMID: 27084341]","volume":"16","author":"Okuma","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2018.10.018_bib0160","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.rmr.2017.11.007","article-title":"[Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma]","volume":"35","author":"Berghmans","year":"2018","journal-title":"Rev. Mal. Respir."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0165","first-page":"11","article-title":"WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies","author":"Oji","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2018.10.018_bib0170","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0175","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S1556-0864(18)30386-1","article-title":"112O Primary result of an investigator-initiated phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study (NCCH1505)","volume":"13","author":"Seto","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2018.10.018_bib0180","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.lungcan.2017.01.015","article-title":"Autoimmune paraneoplastic syndromes associated to lung cancer: a systematic review of the literature","volume":"106","author":"Durieux","year":"2017","journal-title":"Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218306020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218306020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:23:19Z","timestamp":1759234999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500218306020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":36,"alternative-id":["S0169500218306020"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.10.018","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic treatments for thymoma and thymic carcinoma: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}